Abstract
Autoantibodies to topoisomerase I (topo I), RNA polymerase III (RNAPIII), centromere, U3RNP/fibrillarin, Th, PM-Scl, and U1RNP found in scleroderma (SSc) are associated with unique clinical subsets. The effects of race and gender on autoantibody prevalence and clinical manifestations were examined. Autoantibodies in sera from 105 SSc (include 75 Caucasian, 24 African-American, 6 others; 89 females and 16 males) were analyzed by immunofluorescence and immunoprecipitation. Clinical information was from database. SSc-related autoantibodies seldom coexist except for anti-topo I and anti-U1RNP. Anti-topo I (35% vs 15%), anti-U3RNP (30% vs 3%, p = 0.0005), and anti-U1RNP (30% vs 13%) were more common in African-Americans vs Caucasians. Anti-centromere (17%) and anti-PM-Scl (only in 8% of female) were found only in Caucasians. In race/gender combination, all three African-American males had anti-topo I (p = 0.04). Anti-U3RNP (35% vs 3%, p = 0.0005) and anti-U1RNP were common in African-American females. In African-American, all nucleolar dominant staining sera had anti-U3RNP; nuclear pattern was topo I (50%), U1RNP (19%), and RNAPIII (13%). In Caucasian, nucleolar was anti-Th (43%) and PM-Scl (29%); nuclear pattern was RNAPIII (29%), topo I (24%), and U1RNP (18%). Anti-topo I, anti-RNAPIII, and anti-U3RNP were associated with diffuse SSc while anti-centromere, anti-Th, and anti-U1 with limited disease. Proximal scleroderma was less common in African-American with anti-topo I (38% vs 91% in Caucasian, p = 0.04). The production of SSc-related autoantibodies is gender and race dependent, and this can be highly relevant in understanding their clinical significance.
Similar content being viewed by others
References
Satoh M, Chan EKL, Sobel ES, Kimpel DL, Yamasaki Y, Narain S, Mansoor R, Reeves WH (2007) Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol 3:721–738
Satoh M, Vazquez-Del Mercado M, Chan EK (2009) Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 19:219–228
Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35:35–42
Steen VD (2008) The many faces of scleroderma. Rheum Dis Clin North Am 34:1–15
Ceribelli A, Cavazzana I, Franceschini F, Airo P, Tincani A, Cattaneo R, Pauley BA, Chan EK, Satoh M (2010) Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 37:2071–2075
Gussin HA, Ignat GP, Varga J, Teodorescu M (2001) Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 44:376–383
Hamidou MA, Audrain MA, Masseau A, Agard C, Moreau A (2006) Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis. Clin Rheumatol 25:542–543
Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ (2010) Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality? Autoimmun Rev 9:755–760
Cavazzana I, Angela C, Paolo A, Stefania Z, Angela T, Franco F (2009) Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev 8:580–584
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590
Satoh M, Ajmani AK, Ogasawara T, Langdon JJ, Hirakata M, Wang J, Reeves WH (1994) Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest 94:1981–1989
Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA Jr, Wright TM (1999) Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 42:465–474
LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576
Nadashkevich O, Davis P, Fritzler MJ (2004) A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 10:CR615–CR621
Welting TJ, Raijmakers R, Pruijn GJ (2003) Autoantigenicity of nucleolar complexes. Autoimmun Rev 2:313–321
Harris ML, Rosen A (2003) Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15:778–784
Walker UA, Tyndall A, Czirjak L, Denton CP, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Matucci-Cerinic M (2009) Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 68:856–862
Medsger TAJr (2001) Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ (ed) Arthritis and allied conditions a textbook of rheumatology, vol 2, 14th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1590–1624
Yamasaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR, Narain S, Richards HB, Chan EK, Reeves WH et al (2006) Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 54:3051–3056
Wiik AS, Hoier-Madsen M, Forslid J, Charles P, Meyrowitsch J (2010) Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 35:276–290
Dellavance A, Gallindo C, Soares MG, da Silva NP, Mortara RA, Andrade LE (2009) Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern. Rheumatology (Oxford) 48:632–637
Okano Y, Medsger TA Jr (1990) Autoantibody to Th ribonucleoprotein (nucleolar 7–2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 33:1822–1828
Okano Y, Steen VD, Medsger TAJ (1992) Autoantibody to U3 nucleolar ribonucleoprotein(fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 35:95–100
Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr (1984) Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 27:125–131
LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205
Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444
Maddison PJ (2000) Mixed connective tissue disease: overlap syndromes. Baillières Best Pract Res Clin Rheumatol 14:111–124
Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner EH (1986) Scl 70 antibody—a specific marker of systemic sclerosis. Br J Dermatol 115:393–401
Cruz M, Mejia G, Lavalle C, Cortes JJ, Reyes PA (1988) Antinuclear antibodies in scleroderma, mixed connective tissue disease and “primary” Raynaud’s phenomenon. Clin Rheumatol 7:80–86
Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr (2007) Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 34:104–109
Codullo V, Cavazzana I, Bonino C, Alpini C, Cavagna L, Cozzi F, Del Papa N, Franceschini F, Guiducci S, Morozzi G et al (2009) Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol 36:1464–1469
Faucher B, Stein P, Granel B, Weiller PJ, Disdier P, Serratrice J, Harle JR, Durand JM, Frances Y, Guis S et al (2010) Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma. Eur J Intern Med 21:114–117
Acknowledgments
We would like to thank Marlene Sarmiento, Annie Chan, and UF GCRC staff for assistance with clinical data collection. This study was supported by NIH grant R01-AR40391 and M01R00082 from the US Public Health Service and by generous gifts from Lupus Link, Inc. (Daytona Beach, FL, USA) and Mr. Lewis M. Schott to the University of Florida Center for Autoimmune Disease.
Disclosures
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Krzyszczak, M.E., Li, Y., Ross, S.J. et al. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol 30, 1333–1339 (2011). https://doi.org/10.1007/s10067-011-1751-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-011-1751-0